MorphoSys MOR208C204, A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

September 17, 2018
https://clinicaltrials.gov/ct2/show/NCT02763319
Cancer - Lymphoma
Principal Investigator: Philip Kuriakose, MD
lymphoma, B-cell
Accepting Participants